FILAMENT HEALTH ANNOUNCES TWO PHASE 2 RESEARCH TRIALS IN PARTNERSHIP WITH UNIVERSITY COLLEGE LONDON
VANCOUVER, BC, July 24, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) (" Filament" or the " Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has partnered with University College London (UCL) to supply its botanical psilocybin drug candidate, PEX010, for two phase 2 research trials. The Medicines and Healthcare Products Regulatory Agency (MHPRA)-approved trials will explore the effects of PEX010 on brain function, perception, and psychological wellbeing.
"These studies represent two important frontiers in psychedelic research," said Dr. Jeremy I Skipper, Principal Investigator for both trials and Professor at UCL. "We will examine both how preparation methods influence therapeutic and cognitive outcomes, and how psilocybin interacts with sensory and cognitive systems to shape perception. Together, these studies offer valuable insight into the therapeutic potential and fundamental mechanisms of psychedelic compounds. They would not be possible without the support of Filament Health."
The first of the two trials, led by Rosalind McAlpine, is a randomised controlled study evaluating the impact of the Digital Intervention for Psychedelic Preparation, a novel 21-day self-guided programme designed to enhance therapeutic outcomes of psychedelic experiences. Participants are randomly assigned to one of two structured preparatory pathways: a meditation-based intervention or a music-based control condition, both delivered through the same digital platform. Following the 21-day programme, all participants undergo a supervised 25 mg psilocybin session at UCL. The study aims to assess how different preparatory strategies influence the quality of the psychedelic experience, levels of psychological readiness, and changes in mental wellbeing. In addition to these outcomes, the trial evaluates intervention adherence, user engagement, and the acceptability of the digital platform - informing the design of future large-scale efficacy trials.
The second trial, led by Oris Shenyan, Amplifying Experimentall y Induced Hallucinations With "Micro" Doses of Psilocybin, will explore how low doses of psilocybin affect the perception of geometric hallucinations and pareidolia, which is the tendency to see meaningful patterns in ambiguous stimuli – such as seeing faces in clouds. Building on models of excitatory visual cortex dynamics, the study will assess how low dose psilocybin-induced neural excitation interacts with external sensory input to shape hallucinatory experiences under controlled conditions.
"Understanding how preparation style and dose affect the psychedelic experience is vital for advancing safe, effective psychedelic therapies," said Benjamin Lightburn, Chief Executive Officer and Co‐Founder at Filament Health. "We are proud to support these pioneering studies at one of the world's preeminent research institutions."
PEX010 is authorized for investigation in 53 clinical trials worldwide for 14 mental health indications.
ABOUT FILAMENT HEALTH (OTC:FLHLF)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and on X, Instagram, and LinkedIn.
FORWARD LOOKING INFORMATION
Certain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
40 minutes ago
- Cision Canada
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /CNW/ -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificity and multiplex detection for neurodegenerative disease diagnosis and monitoring. This year's AAIC marks the first public presentation of robust clinical data generated using NULISA to measure brain-derived pTaus alongside over 120 key CNS disease-related proteins, an achievement that could accelerate both early detection and therapeutic monitoring in Alzheimer's and related neurodegenerative conditions. "The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for neurodegenerative diseases," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. These data will be presented during Alamar's product theater on Monday, July 28, 1:20 PM ET, featuring Prof. Jonathan Schott from University College London and the UK DRI, and Dr. Cheryl Wellington from the University of British Columbia. Highlights include: Brain-Derived pTau Performance: The presentation will showcase data from the 1946 Birth Cohort featuring the new brain-derived pTau isoforms using the NULISAseq™ CNS Disease Panel 120 in both presymptomatic and post-AD diagnosis samples, highlighting the superior ability of brain-derived pTaus to predict Alzheimer's disease years before it was diagnosed Correlations with Disease Progression: Data will demonstrate the correlation between brain-derived pTau levels and amyloid and Tau PET imaging Biomarkers for neuropathologies and AD co-pathologies: Analysis of a unique cohort of patients with autopsy-confirmed pathologies with the NULISAseq™ CNS Disease Panel 120 identified biomarkers for detecting neuropathologies and AD co-pathologies. Preclinical research: The NULISAseq™ Mouse Panel 120 demonstrated utility in analysis of plasma and brain homogenate samples from multiple clinical models of AD. The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the scientific community focused on dementia and Alzheimer's research. Every year, the conference gathers leading experts, scientists, clinicians, and stakeholders to share the latest discoveries, foster collaborations, and accelerate the quest for effective diagnostics and therapies. See here for a full list of posters and presentations featuring NULISA data during the AAIC meeting. About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Cision Canada
an hour ago
- Cision Canada
Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference
Analysis of first-in-class CNS-101 study validates that at-home endpoints showed greater separation with Alzheimer's pathology (pTau217) than the benchmark endpoint Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13) over the study time-course BELFAST, Northern Ireland, July 28, 2025 /CNW/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data from their real-world observational study CNS-101 at the Alzheimer's Association International Conference 2025 in Toronto, Ontario, Canada. Using the proprietary NeuLogiq ® Platform to gather data via repeated at-home sampling, the study was conducted in collaboration with the University of Cambridge. Cumulus presented a poster titled, "Frequent at-home multimodal measurements are more sensitive to progression than the gold-standard clinic-based ADAS-Cog composite scale" which featured data confirming repeated home-based digital cognitive endpoints are more sensitive to disease progression than the ADAS-Cog 13 composite benchmark, the primary cognitive scale used in Alzheimer's clinical trials today to determine drug efficacy. Additionally, passive electroencephalography (EEG) markers and naturalistic language-based markers collected with the NeuLogiq Platform are similarly powerful at detecting dementia progression as the ADAS-Cog 13, which requires a trained clinician and takes ~45 minutes to administer. "Clinic-based endpoints reflect snapshots in time, which limits the ability to track true disease progression and therapeutic efficacy in clinical research. Additionally, these endpoints lack sensitivity, objectivity, and are not scalable," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Our CNS-101 study was executed in collaboration with the Cumulus Pharma Advisory Group, which is comprised of leading scientists from ten top pharma companies. This first-in-class study has validated that patients living with Alzheimer's dementia are capable and willing to participate in clinical studies that include at-home longitudinal measures. Our NeuLogiq platform, which includes an award-winning FDA-cleared EEG headset, is user-friendly and suitable for repeated at-home use. We now have evidence that repeated real-world measurements at home provide higher statistical power than ADAS-Cog and could enable leaner study designs. We are deeply grateful to all the study participants and research collaborators." Additional analysis demonstrated that individual digital endpoints can enable streamlined study designs which may reduce overall costs, accelerating results leading to earlier go/no go decisions. In collaboration with the Cumulus Pharma Advisory Group, Cumulus will validate whether a digital composite measure may provide additional study power. "It's promising to see the increased sensitivity and statistical power of digital biomarkers from the wealth of data collected both at home and in the clinic in CNS-101," said Dr. Emer MacSweeney, Co-Founder & CEO of Re:Cognition Health's Brain and Mind Clinics which served as a leading CNS-101 clinical site. "The burden on study participants and patients is an important consideration when designing a clinical study in Alzheimer's Disease. Studies like CNS-101 are important to show the validity and sensitivity of digital biomarkers in developing CNS therapies and reducing the impact on patients and clinicians alike." Alzheimer's is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, difficulty with language and communication, mood swings, and changes in behavior and personality. While there is no known cure, there are currently over one hundred Alzheimer's disease clinical trials underway. In the CNS-101 Study, patients with dementia (N=59, ACE-III scores >60 and ≤88) and a matched cohort of healthy controls (N=60) were recruited across 7 sites in the UK including Cambridge and Oxford Universities and Re:Cognition Health's Brain and Mind Clinics in Plymouth and Guildford, for a 12-month repeated sampling study. Plasma samples were collected to confirm disease pathology. Participants were asked to complete repeated home-based sessions using the platform during the day, and to wear a sleep EEG device at night. Day sessions with a duration of approximately 30 minutes included 8 behavioral assessments on a mobile tablet (memory, executive function, affective processing and language) while synchronized EEG was recorded using the Cumulus 16-lead EEG headset. A staggered longitudinal protocol followed with burst sampling tapering to periodic sampling over the year. Benchmark paper-based assessments (including ADAS-Cog) and self-reported usability were collected at months 0, 6, and 12. Blood plasma was collected at months 6 and 12 for later biomarker analysis. Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit About Cumulus Neuroscience With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq ®, an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world's leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer's Disease, depression and schizophrenia. Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient's home – all with an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world's largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.
Cision Canada
3 hours ago
- Cision Canada
Embolx Launches Sniper G3: Revolutionizing Embolization with Enhanced Efficiency, Ease of Use, and Extended Shelf Life
SUNNYVALE, Calif., July 28, 2025 /CNW/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third iteration of the innovative device delivers significant enhancements, including an extended shelf life, improved ease of use, and streamlined preparation, directly addressing critical feedback from physician users. The highly anticipated Sniper G3 features a 24-month shelf life, doubling the longevity of its predecessor. This improvement offers greater inventory flexibility for hospitals and clinics. Designed with direct input from interventional radiologists, Sniper G3 also features improved trackability and a simplified preparation process, significantly reducing pre-procedure setup time. The new prep method eliminates several steps, cutting preparation time down to less than a minute, a crucial gain in fast-paced clinical environments. This focus on user feedback underscores Embolx's commitment to developing intuitive, high-performance tools that enhance clinical workflow. " Sniper G3 truly exemplifies our dedication to innovation driven by physician needs," said Michael Allen, President and CEO of Embolx. " We listened intently to our users and engineered a device that not only extends product longevity and improves performance, but also significantly enhances the ease of use, which translates directly to more efficient procedures. We are incredibly proud of Sniper G3 and its potential to set a new standard in embolization therapy." The Sniper G3 Balloon Occlusion Microcatheter represents a significant leap forward in Embolx's commitment to physician-centric innovation. It is available in all standard lengths and is ready for worldwide distribution. About Embolx Embolx has pioneered advanced pressure-mediated delivery of therapeutics directly into cancerous tumors, prostates, and other anatomical structures and is dedicated to transforming healthcare through the development of innovative technologies. For media inquiries, please contact:
